Med Device Online (guest column by David Amor) — The recent pricing controversy surrounding Mylan may be new to the public, but medtech industry experts have long known that the EpiPen manufacturer has employed various tactics in protecting and maintaining its 90 percent market share of the lucrative epinephrine auto-injector market. One of the most interesting methods that Mylan deployed was the filing of a “Citizen Petition” on Jan. 16, 2015.
…
David Amor, MSBE, CQA is a medtech/ biotech consultant and mobile health entrepreneur who founded Medgineering and adjunct professor in the St. Cloud State University MedTech program, where he teaches courses on risk management and design control.
